Allogene Therapeutics, Inc. (ALLO) Tops Q4 EPS by 4c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q4 EPS of ($0.66), $0.04 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $47 thousand versus the consensus estimate of $60.64 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'
• ScanSource (SCSC) Tops Q4 EPS by 32c